LGND Ligand Pharmaceuticals Inc - Class B

Price (delayed)

$286.29

Market cap

$5.71B

P/E Ratio

28.43

Dividend/share

N/A

EPS

$10.07

Enterprise value

$5.83B

?
Relative Growth: Rel. Growth: 95
Relative Strength: Rel. Strength: 87
Relative Valuation: Rel. Valuation: 56
Relative Profitability: Rel. Profitability: 98

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model ...

Highlights
The gross profit has surged by 59% year-on-year and by 6% since the previous quarter
The revenue has surged by 55% year-on-year and by 6% since the previous quarter
The equity has grown by 17% year-on-year but it has declined by 3% since the previous quarter
The debt has soared by 150% from the previous quarter

Key stats

What are the main financial stats of LGND

LGND stock price

How has the Ligand Pharmaceuticals Inc - Class B stock price performed over time
Intraday
-0.38%
1 week
-2.82%
1 month
-6.28%
1 year
81.99%
YTD
51.42%
QTD
-9.43%

Financial performance

How have Ligand Pharmaceuticals Inc - Class B's revenue and profit performed over time
Revenue
$290.54M
Gross profit
$277.26M
Operating income
$94.73M
Net income
$197.22M
Gross margin
95.4%
Net margin
67.9%
The gross profit has surged by 59% year-on-year and by 6% since the previous quarter
The revenue has surged by 55% year-on-year and by 6% since the previous quarter
Ligand Pharmaceuticals Inc - Class B's net income has increased by 28% from the previous quarter
The net margin has grown by 21% from the previous quarter

Price vs fundamentals

How does LGND's price correlate with its fundamentals

Growth

What is Ligand Pharmaceuticals Inc - Class B's growth rate over time

Valuation

What is Ligand Pharmaceuticals Inc - Class B stock price valuation
P/E
28.43
P/B
5.93
P/S
19.77
EV/EBIT
23.89
EV/EBITDA
20.9
EV/Sales
20.07
LGND's P/E is 30% below its last 4 quarters average of 40.7
Ligand Pharmaceuticals Inc - Class B's EPS has increased by 27% QoQ
LGND's P/B is 128% higher than its 5-year quarterly average of 2.6 and 32% higher than its last 4 quarters average of 4.5
The equity has grown by 17% year-on-year but it has declined by 3% since the previous quarter
The price to sales (P/S) is 87% higher than the 5-year quarterly average of 10.6 and 24% higher than the last 4 quarters average of 15.9
The revenue has surged by 55% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Ligand Pharmaceuticals Inc - Class B business performance
Ligand Pharmaceuticals Inc - Class B's ROIC has soared by 189% YoY
The company's return on equity rose by 24% QoQ
Ligand Pharmaceuticals Inc - Class B's return on sales has increased by 21% QoQ
The ROA has increased by 5% QoQ

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals Inc - Class B financials performed over time
The company's total assets is 79% higher than its total liabilities
The company's total assets has surged by 130% YoY and by 43% QoQ
Ligand Pharmaceuticals Inc - Class B's total liabilities has surged by 128% QoQ
The debt is 17% more than the equity
The debt to equity has soared by 160% from the previous quarter
The debt has soared by 150% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.